

Date Added	Drug Name	Brand Name	Drug Formulation	HD Category	Type of Hazard	Risk of Exposure	Reviewed Date
11/2/2018	Abacavir	Ziagen	Tablet	Non-Antineoplastic	FDA Pregnancy Category C		5/22/2024
11/3/2020	Abacavir/Lamivudine/Zidovudine	Trizivir	Tablet	Non-Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category C		5/22/2024
6/12/2019	Acitretin	Soriatane	Capsule	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
7/23/2020	ado-trastuzumab	Kadcyla	Injection	Antineoplastic	Conjugated monoclonal antibody; FDA Pregnancy Category D	CSTD	5/22/2024
3/26/2021	Altretamine	Hexalen	Capsule	Antineoplastic	FDA Pregnancy Category D		5/22/2024
10/15/2018	Anastrozole	Arimidex	Tablet	Antineoplastic	FDA Pregnancy Category X		5/22/2024
3/26/2021	Arsenic Trioxide	Trisenox	Injection	Antineoplastic	IARC Group 1, Carcinogenic to Humans; NTP: Known To Be Human Carcinogens; FDA Pregnancy Category D	CSTD	5/22/2024
7/23/2020	Azacitidine	Vidaza	Injection	Antineoplastic	IARC Group 2A, Probably Carcinogenic to Humans; NTP: Reasonably Anticipated To Be Human Carcinogens; FDA Pregnancy Category D	CSTD	5/22/2024
11/2/2018	Azathioprine	Azasan; Imuran	Tablet	Non-Antineoplastic	Manufacturer's Safe Handling Guidance IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category D		5/22/2024
7/23/2020	Bendamustine	Bendeka; Treanda	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
10/8/2018	Bicalutamide	Casodex	Tablet	Antineoplastic	FDA Pregnancy Category X		5/22/2024
7/23/2020	Bleomycin	Blenoxane	Injection	Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category D	CSTD	5/22/2024
7/23/2020	Bortezomib	Velcade	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
11/3/2020	Brentuximab vedotin	Adcetris	Injection	Antineoplastic	Conjugated monoclonal antibody; FDA Pregnancy Category D	CSTD	5/22/2024
3/26/2021	Busulfan	Myleran	Tablet	Antineoplastic	IARC Group 1, Carcinogenic to Humans; FDA Pregnancy Category D		5/22/2024
11/3/2020	Cabazitaxel	Jevtana	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
9/9/2019	Cabergoline	Cabaser; Dostinex	Tablet	Reproductive Risk Only	Inhibition of conception and embryo fetal effects at doses below recommended human dose; FDA Pregnancy Category B		5/22/2024
6/10/2019	Capecitabine	Xeloda	Tablet	Antineoplastic	Metabolized to 5-fluorouracil; FDA Pregnancy Category D		5/22/2024
11/2/2018	Carbamazepine	Tegretol; Tegretol-XR	Tablet	Non-Antineoplastic	FDA Pregnancy Category D		5/22/2024
11/2/2018	Carbamazepine	Carbatrol; Equetro	Capsule	Non-Antineoplastic	FDA Pregnancy Category D		5/22/2024
11/2/2018	Carbamazepine	Tegretol	Suspension	Non-Antineoplastic	FDA Pregnancy Category D		5/22/2024
11/2/2018	Carbamazepine	Tegretol	Chewable Tablet	Non-Antineoplastic	FDA Pregnancy Category D		5/22/2024
7/23/2020	Carboplatin	Paraplatin	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
11/3/2020	Carfilzomib	Kyprolis	Injection	Antineoplastic	Special warnings on contraception while taking and 2 weeks post-treatment; FDA Pregnancy Category D	CSTD	5/22/2024
3/26/2021	Carmustine	Bicnu	Injection	Antineoplastic	IARC Group 2A, Probably Carcinogenic to Humans; NTP, Reasonably Anticipated To Be Human Carcinogens; FDA Pregnancy Category D	CSTD	5/22/2024
7/16/2019	Chlorambucil	Leukeran	Tablet	Antineoplastic	IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category D		5/22/2024
6/10/2019	Cidofovir	Vistide	Injection	Non-Antineoplastic	FDA Pregnancy Category C		5/22/2024
7/23/2020	Cisplatin	CDDP	Injection	Antineoplastic	IARC Group 2A, Probably Carcinogenic to Humans; NTP, Reasonably Anticipated To Be Human Carcinogens; FDA Pregnancy Category D	CSTD	5/22/2024
6/12/2019	Clomiphene	Clomid; Serophene	Tablet	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
12/10/2018	Clonazepam	Klonopin	Tablet	Reproductive Risk Only	Increased risk of congenital abnormalities when taken in first trimester; FDA Pregnancy Category D		5/22/2024
12/10/2018	Colchicine	Colcrys	Tablet	Reproductive Risk Only	FDA Pregnancy Category C		5/22/2024
10/8/2018	Cyclophosphamide	Cytoxan	Injection	Antineoplastic	IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category D	CSTD	5/22/2024
10/8/2018	Cyclophosphamide	Cytoxan	Tablet	Antineoplastic	IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category D		5/22/2024
11/2/2018	Cyclosporine	Gengraf; Neoral; Sandimmune	Solution	Non-Antineoplastic	IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category C		5/22/2024
11/2/2018	Cyclosporine	Restasis	Eye Drop	Non-Antineoplastic	IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category C		5/22/2024
11/2/2018	Cyclosporine	Sandimmune; Gengraf; Neoral	Capsule	Non-Antineoplastic	IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category C		5/22/2024
11/3/2020	Cytarabine	Cytosar-U	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
7/23/2020	Dacarbazine	DTIC-Dome; DTIC; DIC; Imidazole Carboxamide	Injection	Antineoplastic	NTP, Reasonably Anticipated To Be Human Carcinogens; FDA Pregnancy Category C	CSTD	5/22/2024
3/26/2021	Dactinomycin	Cosmegen	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
3/26/2021	Dasatinib	Sprycel	Tablet	Antineoplastic	FDA Pregnancy Category D		5/22/2024
11/3/2020	Daunorubicin	Cerubidine	Injection	Antineoplastic	IARC Group 2B, Probably Carcinogenic to Humans, AKA daunomycin; FDA Pregnancy Category D	CSTD	5/22/2024
7/23/2020	Decitabine	Dacogen	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
11/3/2020	Degarelix	Firmagon	Injection	Antineoplastic	FDA Pregnancy Category X	CSTD	5/22/2024
12/10/2018	Dinoprostone	Cervidil; Prostin E2	Vaginal Insert	Reproductive Risk Only	Hazardous only for women in late pregnancy; FDA Pregnancy Category C		5/22/2024

12/10/2018	Dinoprostone	Prepidil	Vaginal Gel	Reproductive Risk Only	FDA Pregnancy Category C		5/22/2024
11/2/2018	Divalproex	Depakote Sprinkles	Sprinkle Capsule	Non-Antineoplastic	FDA Pregnancy Category D		5/22/2024
11/2/2018	Divalproex	Depakote; Depakote ER	Tablet	Non-Antineoplastic	FDA Pregnancy Category D		5/22/2024
7/23/2020	Docetaxel	Taxotere	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
7/23/2020	Doxorubicin	Adriamycin; Doxil	Injection	Antineoplastic	IARC Group 2A, Probably Carcinogenic to Humans; NTP, Reasonably Anticipated To Be Human Carcinogens; FDA Pregnancy Category D	CSTD	5/22/2024
12/10/2018	Dronedaron	Multaq	Tablet	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
12/10/2018	Dutasteride	Avodart	Capsule	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
12/10/2018	Dutasteride-Tamsulosin	Jalyn	Capsule	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
3/23/2022	enfortumab vedotin-efv	PADCEV	Injection	Antineoplastic	Reproductive Toxicity: Suspected of damaging fertility or the unborn child.	CSTD	5/22/2024
7/21/2019	Entecavir	Baraclude	Tablet	Non-Antineoplastic	FDA Pregnancy Category C		5/22/2024
3/26/2021	Epirubicin	Ellence	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
11/3/2020	Eribulin	Halaven	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
3/26/2021	Erlotinib	Tarceva	Tablet	Antineoplastic	FDA Pregnancy Category D		5/22/2024
9/9/2019	Eslicarbazepine	Aptiom; Zebinix	Tablet	Reproductive Risk Only	FDA Pregnancy Category C		5/22/2024
9/9/2019	Estradiol	Alora; Climara; Dotti; Menostar; Minivelle; Vivelle-Dot	Topical Patch	Non-Antineoplastic	FDA Pregnancy Category X		5/22/2024
11/2/2018	Estradiol	Estrace	Vaginal Cream	Non-Antineoplastic	FDA Pregnancy Category X		5/22/2024
11/2/2018	Estradiol	Estrace	Tablet	Non-Antineoplastic	FDA Pregnancy Category X		5/22/2024
11/2/2018	Estradiol	Estring; Vagifem; Yuvafem	Vaginal Tablet	Non-Antineoplastic	FDA Pregnancy Category X		5/22/2024
9/9/2019	Estrogen-Medroxyprogesterone	Prempro; Premphase	Tablet	Non-Antineoplastic	IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category X		5/22/2024
11/2/2018	Estrogens Conjugated	Premarin	Tablet	Non-Antineoplastic	NTP, Known To Be Human Carcinogens; FDA Pregnancy Category X		5/22/2024
11/2/2018	Estrogens Conjugated	Premarin Intravenous	Injection	Non-Antineoplastic	NTP, Known To Be Human Carcinogens; FDA Pregnancy Category X		5/22/2024
11/2/2018	Estrogens Conjugated	Premarin Vaginal	Vaginal Cream	Non-Antineoplastic	NTP, Known To Be Human Carcinogens; FDA Pregnancy Category X		5/22/2024
6/10/2019	Estropipate	Harmogen, Improvera; Ogen; Ortho-Est; Sulestrex	Tablet	Non-Antineoplastic	FDA Pregnancy Category X		5/22/2024
10/25/2019	Etonogestrel	Nexplanon	Subdermal Implant	Non-Antineoplastic	IARC Group 2B FDA Pregnancy Category X		5/22/2024
7/23/2020	Etoposide	Toposar	Injection	Antineoplastic	IARC Group 1, Carcinogenic to Humans; FDA Pregnancy Category D	CSTD	5/22/2024
10/12/2018	Exemestane	Aromasin	Tablet	Antineoplastic	FDA Pregnancy Category X		5/22/2024
3/23/2022	fam-trastuzumab deruxtecan-NXKI	Enhertu	Injection	Antineoplastic		CSTD	5/22/2024
12/10/2018	Finasteride	Propecia; Proscar	Tablet	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
7/21/2019	Fingolimod	Gilenya	Capsule	Non-Antineoplastic	FDA Pregnancy Category C		5/22/2024

12/10/2018	Fluconazole	Diflucan	IVPB	Reproductive Risk Only	FDA Pregnancy Category C		5/22/2024
12/10/2018	Fluconazole	Diflucan	Suspension	Reproductive Risk Only	FDA Pregnancy Category C		5/22/2024
12/10/2018	Fluconazole	Diflucan	Tablet	Reproductive Risk Only	FDA Pregnancy Category C		5/22/2024
7/23/2020	Fludarabine	Fludara	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
7/23/2020	Fluorouracil	Adrucil; 5-FU	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
7/16/2019	Flutamide	Eulexin	Capsule	Antineoplastic	FDA Pregnancy Category D		5/22/2024
11/2/2018	Fosphenytoin	Cerebyx	Injection	Non-Antineoplastic	FDA Pregnancy Category D		5/22/2024
10/12/2018	Fulvestrant	Faslodex	Injection	Antineoplastic	FDA Pregnancy Category D	Kit requiring no manipulation	5/22/2024
11/3/2020	Ganciclovir	Cytovene	Injection	Non-Antineoplastic	FDA Pregnancy Category C		5/22/2024
11/3/2020	Ganciclovir	Cytovene	Capsule	Non-Antineoplastic	FDA Pregnancy Category C		5/22/2024
7/23/2020	Ganirelix	Orgalutran; Antagon	Injection	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
7/23/2020	Gemcitabine	Gemzar; Infugem	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
11/3/2020	Goserelin	Zoladex	Subcutaneous Implant	Antineoplastic	FDA Pregnancy Category X		5/22/2024
10/18/2021	hydroxyprogesterone	Makena	Injection	Non-Antineoplastic	IARC 2B		5/22/2024
10/12/2018	Hydroxyurea	Droxia; Hydreia; Siklos	Capsule	Antineoplastic	FDA Pregnancy Category D		5/22/2024
7/23/2020	Idarubicin	Idamycin PFS; IDR; Idarubicin PFS	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
7/23/2020	Ifosfamide	Ifex	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
6/10/2019	Imatinib	Gleevec	Tablet	Antineoplastic	FDA Pregnancy Category D		5/22/2024
7/23/2020	Irinotecan	Camptosar; CPT-11; Onivyde	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
11/3/2020	Ixabepilone	Ixempra	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
12/10/2018	Lamivudine- Zidovudine	Combivir	Tablet	Non-Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category C		5/22/2024
11/2/2018	Leflunomide	Arava	Tablet	Non-Antineoplastic	FDA Pregnancy Category X		5/22/2024
3/26/2021	Lenalidomide	Revlimid	Capsule	Non-Antineoplastic	FDA Pregnancy Category X		5/22/2024
10/12/2018	Letrozole	Femara	Tablet	Antineoplastic	FDA Pregnancy Category X		5/22/2024
10/12/2018	Leuprolide	Eligard	Injection	Antineoplastic	FDA Pregnancy Category X	CSTD	5/22/2024
10/12/2018	Leuprolide	Lupron Depot	Injection	Antineoplastic	FDA Pregnancy Category X	Kit requiring no manipulation	5/22/2024
7/25/2019	Levonorgestrel	Kyleena; Liletta; Mirena	Intrauterine Device	Non-Antineoplastic	IARC Group 2B FDA Pregnancy Category X		5/22/2024
7/25/2019	Levonorgestrel	Plan B One-Step	Tablet	Non-Antineoplastic	IARC Group 2B FDA Pregnancy Category X		5/22/2024
11/2/2018	Liraglutide	Victoza	Injection	Non-Antineoplastic	FDA Pregnancy Category C		5/22/2024
3/26/2021	Lomustine	Ceenu	Capsule	Antineoplastic	IARC Group 2A, Probably Carcinogenic to Humans; NTP, Reasonably Anticipated To Be Human Carcinogens; FDA Pregnancy Category D		5/22/2024
9/21/2022	Loncastuximab	Zynlonta	Injection	Antineoplastic		CSTD	5/22/2024
10/5/2023	lurbinectedin	Zepzelca	Injection	Antineoplastic	Fetal Risk Cannot be Ruled Out	CSTD	5/22/2024
3/26/2021	Macitentan	Opsumit	Tablet	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
11/2/2018	Medroxyprogesterone Acetate	Depo-Provera	Injection	Non-Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category X		5/22/2024
11/2/2018	Medroxyprogesterone Acetate	Provera	Tablet	Non-Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category X		5/22/2024
10/12/2018	Megestrol	Megace	Tablet	Antineoplastic	FDA Pregnancy Category X		5/22/2024
10/12/2018	Megestrol	Megace ES	Suspension	Antineoplastic	FDA Pregnancy Category X	obtained UD	5/22/2024
3/26/2021	Melphalan	Alkeran	Injection	Antineoplastic	IARC Group 1 Carcinogen; NTP "Known to be human carcinogen"; FDA Pregnancy Category D	CSTD	5/22/2024
3/26/2021	Melphalan	Alkeran	Tablet	Antineoplastic	IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category D		5/22/2024

6/10/2019	Mercaptopurine	Purinethol	Tablet	Antineoplastic	FDA Pregnancy Category D		5/22/2024
11/2/2018	Methimazole	Tapazole	Tablet	Non-Antineoplastic	FDA Pregnancy Category D		5/22/2024
7/23/2020	Methotrexate	MTX	Injection	Antineoplastic	FDA Pregnancy Category X	CSTD	5/22/2024
10/12/2018	Methotrexate	Rheumatrex; Trexall	Tablet	Antineoplastic	FDA Pregnancy Category X		5/22/2024
6/12/2019	Methylergonovine	Methergine	Injection	Reproductive Risk Only	FDA Pregnancy Category C		5/22/2024
6/12/2019	Methylergonovine	Methergine	Tablet	Reproductive Risk Only	FDA Pregnancy Category C		5/22/2024
12/6/2019	Mifepristone	Mifeprex	Tablet	Reproductive Risk Only	When given to pregnant women, results in termination of pregnancy; FDA Pregnancy Category X		5/22/2024
12/10/2018	Misoprostol	Cytotec	Tablet	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
7/23/2020	Mitomycin	MTC; Mutamycin	Injection	Antineoplastic	Manufacturer's Safe Handling Guidance; IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category D	CSTD	5/22/2024
3/26/2021	Mitotane	Lysodren	Tablet	Antineoplastic	IARC Group 2B; FDA Pregnancy Category D		5/22/2024
11/3/2020	Mitoxantrone	Novantrone	Injection	Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category D	CSTD	5/22/2024
11/2/2018	Mycophenolate Acid	Cellcept	Tablet	Non-Antineoplastic	FDA Pregnancy Category D		5/22/2024
11/2/2018	Mycophenolate Mofetil	Cellcept	Suspension	Non-Antineoplastic	FDA Pregnancy Category D		5/22/2024
11/2/2018	Mycophenolate Mofetil	Cellcept	Capsule	Non-Antineoplastic	FDA Pregnancy Category D		5/22/2024
7/25/2019	Nevirapine	Viramune	Tablet	Non-Antineoplastic	FDA Pregnancy Category B		5/22/2024
8/2/2019	Norethindrone	Many Brand Names: Camila; Deblitane; Errin; heather; Incassia; Jencycla, etc	Tablet	Non-Antineoplastic	IARC Group 2B FDA Pregnancy Category X		5/22/2024
7/23/2020	Oxaliplatin	Eloxatin	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
11/2/2018	Oxcarbazepine	Oxtellar XR; Trileptal	Tablet	Non-Antineoplastic	FDA Pregnancy Category C		5/22/2024
11/2/2018	Oxcarbazepine	Trileptal	Suspension	Non-Antineoplastic	FDA Pregnancy Category C		5/22/2024
12/10/2018	Oxytocin	Pitocin	IVPB	Reproductive Risk Only	FDA Pregnancy Category C		5/22/2024
12/10/2018	Oxytocin	Pitocin	Injection	Reproductive Risk Only	FDA Pregnancy Category C		5/22/2024
7/23/2020	Paclitaxel	Onxol; Taxol; Abraxane	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
12/10/2018	Pamidronate	Aredia	Injection	Reproductive Risk Only	FDA Pregnancy Category D		5/22/2024
9/9/2019	Paroxetine	Paxil	Suspension	Reproductive Risk Only	FDA Pregnancy Category D		5/22/2024
12/10/2018	Paroxetine	Paxil	Tablet	Reproductive Risk Only	FDA Pregnancy Category D		5/22/2024
12/10/2018	Paroxetine	Paxil CR	ER Tablet	Reproductive Risk Only	FDA Pregnancy Category D		5/22/2024
7/23/2020	Pemetrexed	Alimta	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024

7/23/2020	Pertuzumab	Perjeta	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
12/14/2023	Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf	Phesgo	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
5/6/2024	Phenol 89%	Pedinol EZ Swabs	Swab	NA	NA		5/22/2024
8/31/2019	Phenoxybenzamine	Dibenzyliline	Capsule	Non-Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category C		5/22/2024
12/7/2018	Phenytoin	Dilantin	Injection	Non-Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; NTP, Reasonably Anticipated To Be Human Carcinogens; FDA Pregnancy Category D		5/22/2024
12/7/2018	Phenytoin	Dilantin	Suspension	Non-Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; NTP, Reasonably Anticipated To Be Human Carcinogens; FDA Pregnancy Category D		5/22/2024
12/7/2018	Phenytoin	Dilantin	Tablet	Non-Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; NTP, Reasonably Anticipated To Be Human Carcinogens; FDA Pregnancy Category D		5/22/2024
12/7/2018	Phenytoin	Dilantin	Capsule	Non-Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; NTP, Reasonably Anticipated To Be Human Carcinogens; FDA Pregnancy Category D		5/22/2024
3/23/2022	Polatuzumab Vedotin-piinq	Polivy	Injection	Antineoplastic	Cytotoxic; Developmental toxicity	CSTD	5/22/2024
3/26/2021	Pralatrexate	Folotyn	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
11/3/2020	Probenecid/Colchicine	Colbenemid	Tablet	Reproductive Risk Only	FDA Pregnancy Category C		5/22/2024
3/26/2021	Progesterone	Endometrin	Vaginal Insert	Non-Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; NTP, Reasonably Anticipated To Be Human Carcinogens		5/22/2024
12/7/2018	Progesterone	Progesterone Injection	Injection	Non-Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; NTP, Reasonably Anticipated To Be Human Carcinogens		5/22/2024
12/7/2018	Progesterone	Prometrium	Capsule	Non-Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; NTP, Reasonably Anticipated To Be Human Carcinogens		5/22/2024
12/7/2018	Propylthiouracil	PTU	Tablet	Non-Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; NTP, Reasonably Anticipated To Be Human Carcinogens; FDA Pregnancy Category D		5/22/2024
12/7/2018	Raloxifene	Evista	Tablet	Non-Antineoplastic	FDA Pregnancy Category X		5/22/2024
12/7/2018	Rasagiline	Azilect	Tablet	Non-Antineoplastic	FDA Pregnancy Category C		5/22/2024
6/12/2019	Ribavirin	RibaTab	Capsule	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
3/26/2021	Riociguat	Adempas	Tablet	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
11/3/2020	Romidepsin	Istodax	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
3/23/2022	sacituzumab govitecan-HZIY	Trodelyv	Injection	Antineoplastic		CSTD	5/22/2024
12/7/2018	Sirolimus	Rapamune	Tablet	Non-Antineoplastic	FDA Pregnancy Category C		5/22/2024
12/7/2018	Spirololactone	Aldactone	Tablet	Non-Antineoplastic	FDA Pregnancy Category C		5/22/2024
3/26/2021	Sunitinib	Sutent	Capsule	Antineoplastic	FDA Pregnancy Category D		5/22/2024
10/18/2021	Tacrolimus	Prograf	Topical Ointment	Non-Antineoplastic	FDA Pregnancy Category C		5/22/2024
12/7/2018	Tacrolimus	Prograf	Capsule	Non-Antineoplastic	FDA Pregnancy Category C		5/22/2024
10/12/2018	Tamoxifen	Nolvadex	Tablet	Antineoplastic	IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category D		5/22/2024
12/10/2018	Temazepam	Restoril	Capsule	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
7/15/2019	Temozolamide	Temodar	Capsule	Antineoplastic	FDA Pregnancy Category D		5/22/2024
3/26/2021	Temsirrolimus	Torisel	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
9/12/2019	Testosterone	Androderm	Topical Patch	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
9/12/2019	Testosterone	AndroGel; Axiron; Fortesta; Testim; Vogelxo	Topical Gel	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
9/12/2019	Testosterone	Aveed; Delatestryl; Depo-Testosterone; Depo-Testadiol; Ditate-DS; Jatenzo; Testopel; Xyosted	Injection	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
3/26/2021	Thalidomide	Thalomid	Capsule	Non-Antineoplastic	FDA Pregnancy Category X		5/22/2024

3/26/2021	Thiotepa	Thioplex	Injection	Antineoplastic	IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category D	CSTD	5/22/2024
3/23/2022	Tisotumab Vedotin-tftv	Tivdak	Injection	Antineoplastic		CSTD	5/22/2024
12/18/2018	Topiramate	Qudexy XR; Topamax; Trokendi XR	Tablet	Reproductive Risk Only	FDA Pregnancy Category D		5/22/2024
7/23/2020	Topotecan	Hycamtin	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
6/3/2022	Trabectedin	Yondelis	Injection	Antineoplastic	Cytotoxic; Genotoxic	CSTD	5/22/2024
9/12/2019	Tretinoin	Avita; Refissa; Renova; Retin-A; Tretin-X	Topical Cream	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
9/12/2019	Tretinoin	Atralin; Retin-A Micro; Retin-A	Topical Gel	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
6/12/2019	Tretinoin	Vesanoid	Capsule	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
11/3/2020	Triptorelin	Trelstar	Injection	Antineoplastic	FDA Pregnancy Category X	CSTD	5/22/2024
9/9/2019	Valganciclovir	Valcyte	Tablet	Non-Antineoplastic	FDA Pregnancy Category C		5/22/2024
12/18/2018	Valproate	Depakene; Depacon;	Capsule	Reproductive Risk Only	FDA Pregnancy Category D		5/22/2024
3/27/2023	Valproate Sodium	Depacon	Injection	Reproductive Risk Only	FDA Pregnancy Category D		5/22/2024
12/18/2019	Valproic Acid	Depakene; Depacon;	Syrup	Reproductive Risk Only	FDA Pregnancy Category D		5/22/2024
7/23/2020	Vinblastine	VLB	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
7/23/2020	Vincristine	VCR; Vincasar PFS; Marquibo	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
7/23/2020	Vinorelbine	Navelbine	Injection	Antineoplastic	FDA Pregnancy Category D	CSTD	5/22/2024
9/12/2019	Voriconazole	Vfend IV	Injection	Reproductive Risk Only	FDA Pregnancy Category D		5/22/2024
6/12/2019	Voriconazole	Vfend	Tablet	Reproductive Risk Only	FDA Pregnancy Category D		5/22/2024
12/18/2018	Warfarin	Coumadin	Tablet	Reproductive Risk Only	FDA Pregnancy Category X		5/22/2024
12/10/2018	Zidovudine	Retrovir	Injection	Non-Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category C		5/22/2024
12/10/2018	Zidovudine	Retrovir	Solution	Non-Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category C		5/22/2024
12/10/2018	Zidovudine	Retrovir	Tablet	Non-Antineoplastic	IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category C		5/22/2024
12/18/2018	Ziprasidone	Geodon	Injection	Reproductive Risk Only	FDA Pregnancy Category C		5/22/2024
12/18/2018	Ziprasidone	Geodon	Capsule	Reproductive Risk Only	FDA Pregnancy Category C		5/22/2024
9/21/2022	ziv-Aflibercept	Zaltrap	Injection	Antineoplastic	FDA Pregnancy Category C	CSTD	5/22/2024
12/18/2018	Zoledronic Acid	Reclast	IVPB	Reproductive Risk Only	FDA Pregnancy Category D		5/22/2024

12/18/2018	Zoledronic Acid	Zometa	Injection	Reproductive Risk Only	FDA Pregnancy Category D		5/22/2024
12/18/2018	Zonisamide	Zonegran	Capsule	Reproductive Risk Only	FDA Pregnancy Category D		5/22/2024